EarningsQ2 2026 Earnings Report
MX:MTLSN Q2 2026 EPS Results
Actual EPS$1.23
Consensus EPS$0.82
Beat/MissBeat by +$0.41
One Year Ago EPS$0.00
MX:MTLSN Q2 2026 Revenue Results
Actual Revenue$1.48B
Expected Revenue$1.40B
Beat/MissBeat by +$78.96M
YoY Revenue Growth+10.88%
Earnings Announcement Details
QuarterQ2 2026
Date08/27/2026
TimeBefore Open
Conference CallThursday, August 27, 2026
MX:MTLSN Upcoming Earnings
Materialise's next earnings date is estimated for October 28, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:MTLSN Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a predominantly positive picture: healthy consolidated revenue growth (+8% Q2), clear margin and profitability improvements (adjusted EBITDA +16%, adjusted EBIT expansion), strong cash generation and net cash position, and strategic product and portfolio actions (CO-AM launches, Replasia investment, divestments) that position the company for scalable growth. Offsetting risks include a modest decline in Software revenue and near-term seasonality/costs (asset impairment, working capital increase), and ongoing weakness in certain Manufacturing subsegments (prototyping demand). On balance, the operational and financial momentum and the upgrade to adjusted EBIT guidance outweigh the contained headwinds reported.Company Guidance
Consolidated Revenue Growth
Q2 2026 consolidated revenue of EUR 70.1 million, up >8% year-over-year; H1 2026 revenue EUR 136.3 million, up nearly 4% year-over-year.
Improved Profitability and Margins
Q2 adjusted EBITDA of EUR 9.6 million (up ~16% YoY) with an adjusted EBITDA margin of 13.7%; Q2 adjusted EBIT of EUR 3.9 million and adjusted EBIT margin expanded to 5.5%; H1 adjusted EBIT EUR 6.4 million (margin 4.7%).
Strong Medical Segment Performance
Medical revenue grew >12% YoY in Q2 and represented 53% of total revenue; Medical Devices grew 19% while Medical adjusted EBITDA reached EUR 11.6 million (31% EBITDA margin); H1 Medical revenue ~EUR 70 million, up nearly 10%.
Aerospace and Manufacturing Momentum
Manufacturing revenue grew nearly 7% YoY to EUR 23.6 million in Q2 despite divestments; Aerospace revenue growth of 40% in Q2 highlighted as a key strength; Manufacturing adjusted EBITDA improved to -EUR 0.3 million (from -EUR 0.8 million prior year).
Cash Generation and Strong Balance Sheet
Cash reserves EUR 133.7 million and gross debt reduced to EUR 59.5 million resulting in net cash EUR 74.2 million (up EUR 3.4 million year-to-date); Q2 operating cash flow >EUR 8 million, H1 operating cash flow EUR 50 million; H1 free cash flow >EUR 11.4 million (almost double prior year).
Strategic Portfolio and Product Moves
CO-AM Pro released one month ahead of schedule (May 15), CO-AM Bricks released and early-adopter programs started for CO-AM NPI and CO-AM Enterprise; investment in Replasia to expand hip-preservation solutions; completed divestments of RapidFit (Apr 30) and Eyewear (Jul 1) while retaining 20% stake in Eyewear to sharpen focus on higher-growth segments.
Upgraded Profitability Guidance
Full-year 2026 revenue guidance reaffirmed at EUR 273–283 million (absorbing divestments) and full-year adjusted EBIT guidance increased to EUR 12–14 million (from prior EUR 10–12 million).
MX:MTLSN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed